CS
MOLN

Credit Suisse’s Molecular Partners MOLN Stock Holding History

Credit Suisse’s Portfolio MOLN Stock Details MOLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-865
Closed -$6K – 4184
2022
Q2 		$6K Buy
+865
New +$8.91K ﹤0.01% 3755

Other funds holding MOLN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Credit Suisse's MOLN Position: Q3 2022 in Review

Credit Suisse sold out of Molecular Partners (MOLN) in Q3 2022, closing a stake of 865 shares — an estimated $6K sold.

Credit Suisse first reported a position in MOLN in Q2 2022 and held it in 1 quarter. The position peaked at $6K in Q2 2022. 8 funds tracked by Wall St. Rank hold MOLN as of Q3 2022.

  • Credit Suisse reported no remaining Molecular Partners position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 865 Molecular Partners shares in Q3 2022, an estimated $6K.
  • Credit Suisse first reported a position in Molecular Partners in Q2 2022 and held it in 1 quarter.
  • Credit Suisse's Molecular Partners position peaked at $6K in Q2 2022.
  • 8 funds tracked by Wall St. Rank held Molecular Partners as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.